A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase
- 23 December 1994
- journal article
- clinical trial
- Published by Elsevier in Life Sciences
- Vol. 56 (5) , 319-326
- https://doi.org/10.1016/0024-3205(94)00954-6
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primatesJournal of the Neurological Sciences, 1992
- The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodentsPharmacology Biochemistry and Behavior, 1991
- Mechanisms of cholinesterase inhibition in senile dementia of the alzheimer type: Clinical, pharmacological, and therapeutic aspectsDrug Development Research, 1988
- A long-lasting cholinesterase inhibitor affecting neural and behavioral processesPharmacology Biochemistry and Behavior, 1987
- Muscarinic Binding and Choline Acetyltransferase in Postmortem Brains of Demented PatientsCanadian Journal of Neurological Sciences, 1986
- Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementiaEuropean Journal of Biochemistry, 1986
- A monoclonal antibody assay technique for plasma and red cell acetylcholinesterase activity in Alzheimer's diseaseJournal of the Neurological Sciences, 1986
- Alzheimer's Disease: A Disorder of Cortical Cholinergic InnervationScience, 1983
- Presynaptic Cholinergic Dysfunction in Patients with DementiaJournal of Neurochemistry, 1983
- Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal ForebrainScience, 1982